Full Text
Managed care Organization Budget impact of adding Recombinant Factor VIII FC fusion protein (RFVIIIFC) to the formulary for the treatment of Hemophilia A

Abstract

Authors

B.C. Buckley T.P. Livingston A. Eldar-Lissai E.C. Hall

Back to Volume 18, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×